Cell Bio Human Tech셀바이오휴먼텍
318160 · KOSDAQ · ₩318160 · 셀바이오휴먼텍
₩6,100▼ ₩150 (2.40%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | ₩51B | ₩28B | ₩27B |
| Cost of sales | ₩32B | ₩19B | ₩20B |
| Gross profit | ₩19B | ₩9B | ₩7.7B |
| Operating income | ₩9.3B | ₩4B | ₩3.1B |
| Net income | ₩8.7B | ₩4.4B | −₩1.9B |
| Net income to shareholders | ₩8.7B | ₩4.4B | −₩1.9B |
Balance sheet
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Total assets | ₩88B | ₩53B | ₩53B |
| Current assets | ₩44B | ₩24B | ₩27B |
| Cash and equivalents | ₩16B | ₩3.1B | ₩4.1B |
| Total liabilities | ₩29B | ₩6.5B | ₩8.6B |
| Current liabilities | ₩19B | ₩6.3B | ₩8.6B |
| Borrowings | ₩20B | ₩3.7B | ₩5.9B |
| Total equity | ₩59B | ₩46B | ₩45B |
| Shareholders' equity | ₩57B | ₩46B | ₩45B |
Cash flow
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Cash from operations | ₩1.5B | ₩9.3B | ₩1.8B |
| Capital spending | ₩6.6B | ₩2B | ₩628M |
| Free cash flow | −₩5.2B | ₩7.2B | ₩1.1B |
Consolidated where available. Amounts in won.
Also known as: Cell Bio Human Tech / 셀바이오휴먼텍 / 318160 / KRX:318160
Source: KRX statistical information